STOCK TITAN

Hedge fund group discloses 2.3% Enanta (NASDAQ: ENTA) holding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Enanta Pharmaceuticals, Inc. received an amended Schedule 13G/A showing institutional investors led by Millennium entities holding a small, passive stake in its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 665,953 shares, representing 2.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 670,428 shares, also equal to 2.3% of the class, as of the event date December 31, 2025.

The filing states that these securities are not held for the purpose of changing or influencing control of Enanta and are reported on a Schedule 13G/A, which is used for passive ownership. The filing also confirms that the reporting persons each own 5% or less of Enanta’s outstanding common stock. A joint filing agreement among the reporting entities and Israel A. Englander is attached as an exhibit.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Integrated Core Strategies (US) LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:01/16/2026
Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:01/16/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:01/16/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:01/16/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of January 16, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake in Enanta Pharmaceuticals (ENTA) is reported in this Schedule 13G/A?

The filing reports that Integrated Core Strategies (US) LLC beneficially owns 665,953 shares, and that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each beneficially own 670,428 shares of Enanta Pharmaceuticals common stock.

What percentage of Enanta (ENTA) common stock do the reporting persons own?

Each reporting person in the filing — Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander — reports beneficial ownership of 2.3% of Enanta’s common stock.

Is the Millennium-related ownership in Enanta (ENTA) passive or for control purposes?

The certification states that the securities were not acquired and are not held for the purpose of, or with the effect of, changing or influencing the control of Enanta Pharmaceuticals. The position is reported on a Schedule 13G/A, which is used for passive ownership.

Who are the reporting persons in this Enanta (ENTA) Schedule 13G/A amendment?

The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The Millennium entities are organized in Delaware, and Mr. Englander is a citizen of the United States.

What is the event date for the ownership reported in this Enanta (ENTA) filing?

The ownership information in this Schedule 13G/A amendment is reported as of the event date December 31, 2025.

Does any reporting person own more than 5% of Enanta (ENTA) shares?

No. Under Item 5, the filing indicates ownership of 5 percent or less of the class, and each reporting person shows a 2.3% stake.

Is there a joint filing agreement among the Enanta (ENTA) reporting persons?

Yes. The document lists Exhibit I as a Joint Filing Agreement dated January 16, 2026, among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Enanta Pharmaceuticals Inc

NASDAQ:ENTA

ENTA Rankings

ENTA Latest News

ENTA Latest SEC Filings

ENTA Stock Data

363.96M
27.52M
6.63%
86.53%
13.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WATERTOWN